These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10840412)

  • 1. Complete androgen blockade for prostate cancer: what went wrong?
    Laufer M; Denmeade SR; Sinibaldi VJ; Carducci MA; Eisenberger MA
    J Urol; 2000 Jul; 164(1):3-9. PubMed ID: 10840412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.
    Caubet JF; Tosteson TD; Dong EW; Naylon EM; Whiting GW; Ernstoff MS; Ross SD
    Urology; 1997 Jan; 49(1):71-8. PubMed ID: 9000189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
    Collette L; Studer UE; Schröder FH; Denis LJ; Sylvester RJ
    Prostate; 2001 Jun; 48(1):29-39. PubMed ID: 11391684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal ablation therapy for metastatic prostatic carcinoma: a review.
    Leewansangtong S; Soontrapa S
    J Med Assoc Thai; 1999 Feb; 82(2):192-205. PubMed ID: 10087729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined androgen blockade: an update.
    Klotz L
    Urol Clin North Am; 2006 May; 33(2):161-6, v-vi. PubMed ID: 16631454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maximal androgen blockade in metastatic prostatic carcinoma].
    Jørgensen T; Tveter KJ
    Tidsskr Nor Laegeforen; 1997 Jan; 117(3):381-3. PubMed ID: 9064862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Disseminated carcinoma of the prostate: monotherapy or complete androgenic blockade?].
    González Martín M; Gómez Veiga F; Alvarez Castelo L
    Arch Esp Urol; 1997 Dec; 50(10):1067-76. PubMed ID: 9494195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H; Chodak GW; Hirao Y
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiandrogens in the treatment of prostate cancer.
    Wirth MP; Hakenberg OW; Froehner M
    Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life after failure of traditional androgen deprivation therapy.
    Schellhammer P
    Urol Oncol; 2012; 30(4 Suppl):S10-4. PubMed ID: 22795075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined castration and androgen blockade therapy in prostate cancer. Conclusions.
    Denis L; Mettlin C
    Cancer; 1990 Sep; 66(5 Suppl):1086-9. PubMed ID: 2203520
    [No Abstract]   [Full Text] [Related]  

  • 20. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.
    Bennett CL; Tosteson TD; Schmitt B; Weinberg PD; Ernstoff MS; Ross SD
    Prostate Cancer Prostatic Dis; 1999 Jan; 2(1):4-8. PubMed ID: 12496859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.